| |
Harvoni for Acute HCV Study Enrolling
|
| |
| |
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (SWIFT-C) - Study Enrolling
Details and site contacts at
https://clinicaltrials.gov/ct2/show/NCT02128217?term=SWIFT-C&rank=1
Purpose: "People who are recently infected with HCV have a great chance of being cured of the infection when they are treated with a combination of two drugs within the first 6 months of being infected. This study is being done to see if a combination of two new drugs in one pill can replace the old drugs to provide a safer, more effective, and better tolerated treatment for new HCV infection. The names of the new drugs are ledipasvir (LDV) and sofosbuvir (SOF), and they will replace pegylated-interferon alfa (PEG-IFN, a drug given as a weekly injection under the skin). The fixed-dose combination of LDV and SOF (LDV/SOF) has been approved by the Food and Drug Administration (FDA)...[Study participants] will receive 8 weeks of LDV/SOF..."
There are many sites throughout the USA, listed at the link above, here is NYC site
New York Sites:
7803 Weill Cornell Upton CRS Recruiting
New York, New York, United States, 10065
Contact: Valery Hughes, FNP 212-746-4393 vah9001@med.cornell.edu
Principal Investigator: Marshall J. Glesby, MD
7804 Weill Cornell Chelsea CRS Recruiting
New York, New York, United States, 10010
Contact: Todd Stroberg, R.N., B.S.N. 212-746-4177 tstrober@med.cornell.edu
Principal Investigator: Timothy Wilkin, MD, MPH
|
|
| |
| |
|
|
|
